Fingerprint
Dive into the research topics of 'Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, for relapsed or refractory NHL patients'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, for relapsed or refractory NHL patients
John M. Pagel, Stephen E. Spurgeon, John C. Byrd, Farrukh T. Awan, Ian W. Flinn, Mark C. Lanasa, Amy J. Eisenfeld, Scott C. Stromatt, Ajay K. Gopal
Research output: Contribution to journal › Article › peer-review
32
Scopus
citations